

38. Jorgensen, W. L.; Ravimohan, C. Monte Carlo simulation of differences in free energies of hydration. *J. Chem. Phys.* **1985**, *83*, 3050–3054.
39. Wong, C. E.; McCammon, J. A. Dynamics and design of enzymes and inhibitors. *J. Am. Chem. Soc.* **1986**, *108*, 3830–3832.
40. McCammon, J. A. Computer-aided molecular design. *Science* **1987**, *238*, 486–491.
41. Kollman, P. A. Free energy calculations: applications to chemical and biochemical phenomena. *Chem. Rev.* **1993**, *93*, 2395–2417.
42. Merz, K. M.; Kollman, P. A. Free energy perturbation simulations of the inhibition of thermolysin: prediction of the free energy of binding of a new inhibitor. *J. Am. Chem. Soc.* **1989**, *111*, 5649–5658.
43. Pearlman, D. A.; Charifson, P. S. Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. *J. Med. Chem.* **2001**, *44*, 3417–3423.
44. Pearlman, D. A. Evaluating the molecular mechanics Poisson-Boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase. *J. Med. Chem.* **2005**, *48*, 7796–7807.
45. Reddy, M. R.; Erion, M. D. Calculation of relative binding free energy differences for fructose 1,6-bisphosphatase inhibitors using thermodynamic cycle perturbation approach. *J. Am. Chem. Soc.* **2001**, *123*, 6246–6252.
46. Erion, M. D.; Dang, Q.; Reddy, M. R.; Kasibhatla, S. R.; Huang, J.; Lipscomb, W. N.; van Poelje, P. D. Structure-guided design of amp mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity. *J. Am. Chem. Soc.* **2007**, *129*, 15480–15490.
47. Pierce, A. C.; Jorgensen, W. L. Computational binding studies of orthogonal cyclosporin-cyclophilin pairs. *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 1466–1469.
48. Essex, J. W.; Severance, D. L.; Tirado-Rives, J.; Jorgensen, W. L. Monte Carlo simulations for proteins: binding affinities for trypsin-benzamidine complexes via free energy perturbations. *J. Phys. Chem.* **1997**, *101*, 9663–9669.
49. Plount-Price, M. L.; Jorgensen, W. L. Analysis of binding affinities for celecoxib analogs with COX-1 and COX-2 from docking and Monte Carlo simulations and insight into COX-2/COX-1 selectivity. *J. Am. Chem. Soc.* **2000**, *122*, 9455–9466.
50. Plount-Price, M. L.; Jorgensen, W. L. Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1541–1544.
51. Guimarães, C. R. W.; Boger, D. L.; Jorgensen, W. L. Elucidation of fatty acid amide hydrolase inhibition by potent α -keto heterocycle derivatives from Monte Carlo simulations. *J. Am. Chem. Soc.* **2005**, *127*, 17377–17384.
52. Rizzo, R. C.; Wang, D.-P.; Tirado-Rives, J.; Jorgensen, W. L. Validation of a model for the complex of HIV-1 reverse transcriptase with Sustiva through computation of resistance profiles. *J. Am. Chem. Soc.* **2000**, *122*, 12898–12900.
53. Wang, D.-P.; Rizzo, R. C.; Tirado-Rives, J.; Jorgensen, W. L. Antiviral drug design: Computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 2799–2802.
54. Udier-Blagović, M.; Tirado-Rives, J.; Jorgensen, W. L. Validation of a model for the complex of HIV-1 reverse transcriptase with the novel non-nucleoside inhibitor TMC125. *J. Am. Chem. Soc.* **2003**, *125*, 6016–6017.
55. Blagović, M. U.; Tirado-Rives, J.; Jorgensen, W. L. Structural and energetic analyses for the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogs. *J. Med. Chem.* **2004**, *46*, 2389–2392.
56. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, E.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Béthune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. *J. Med. Chem.* **2004**, *47*, 2550–2560.
57. Jorgensen, W. L.; Thomas, L. T. Perspective on free-energy perturbation calculations for chemical equilibria. *J. Chem. Theor. Comput.* **2008**, *4*, 869–876.